Daiichi Sankyo has agreed to pay $132.5 million to Glycotope to acquire the intellectual property rights for the TA-MUC1 antibody, gatipotuzumab

The payment satisfies all potential clinical, regulatory, and sales milestone payments, as well as royalties from products containing gatipotuzumab, as per the 2018 licensing agreement

In 2018, Daiichi Sankyo in-licensed exclusive rights to develop and commercialize gatipotuzumab worldwide as an ADC from Glycotope

DS-3939 is currently being evaluated in Phase 1/2 clinical trials for various advanced solid tumors, including non-small cell lung cancer, breast cancer, urothelial cancer, ovarian cancer, biliary tract cancer, and pancreatic cancer